<?xml version="1.0" encoding="UTF-8"?>
<record
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd"
    xmlns="http://www.loc.gov/MARC21/slim">

  <leader>01912nam a22001577a 4500</leader>
  <datafield tag="082" ind1=" " ind2=" ">
    <subfield code="a">610</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Ansari, Sara</subfield>
    <subfield code="9">120660</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Analysis of post-COVID comorbidities in Pakistani population /</subfield>
    <subfield code="c">Sara Ansari</subfield>
  </datafield>
  <datafield tag="264" ind1=" " ind2=" ">
    <subfield code="a">Islamabad : </subfield>
    <subfield code="b">SMME- NUST; </subfield>
    <subfield code="c">2022.</subfield>
  </datafield>
  <datafield tag="300" ind1=" " ind2=" ">
    <subfield code="a">61p.</subfield>
    <subfield code="b">Soft Copy</subfield>
    <subfield code="c">30cm</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">Introduction: Long-COVID, is the collective name given to denote persistence of symptoms for
weeks or months in those who have recovered from SARS-COV-2 infection. If the relapsing
symptoms are left undetected, can lead to chronic conditions. Still some work needs to be done
to determine the correlation of the previous illnesses with the severity of post-COVID
symptoms.
Method: A questionnaire survey was spread amongst Pakistani population. About 83 COVID-19
survivors were included in the study, who were asked about any occurrence of symptoms at
recovery, the experience and duration of the post-viral symptoms.
Results: Out of 83 participants, 59(71.7%) experienced relapsing symptoms at 3 weeks from the
onset of the viral infection, with 34(44.6%) having to face those symptoms for 3-4 weeks (postacute COVID). Females were significantly more likely to experience fatigue (p=0.014) and
severity (p=0.032). The presence of symptoms was not associated with any therapy or activity.
The presence of mild symptoms is common after the COVID-19 infection with those already
suffering from anxiety, allergies, hypertension, and diabetes.
Conclusion: This study highlights the importance of assessing those recovering from mild
COVID-19 with acute-fatigue. Moreover, further longitudinal research in this area can help
understand the management of chronic situations. </subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">MS Biomedical Engineering (BME)      </subfield>
    <subfield code="9">119509</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Supervisor : Dr. Muhammad Asim Waris</subfield>
    <subfield code="9">119524</subfield>
  </datafield>
  <datafield tag="856" ind1=" " ind2=" ">
    <subfield code="u">http://10.250.8.41:8080/xmlui/handle/123456789/32028</subfield>
  </datafield>
  <datafield tag="942" ind1=" " ind2=" ">
    <subfield code="2">ddc</subfield>
    <subfield code="c">THE</subfield>
  </datafield>
  <datafield tag="999" ind1=" " ind2=" ">
    <subfield code="c">607824</subfield>
    <subfield code="d">607824</subfield>
  </datafield>
  <datafield tag="952" ind1=" " ind2=" ">
    <subfield code="0">0</subfield>
    <subfield code="1">0</subfield>
    <subfield code="4">0</subfield>
    <subfield code="7">0</subfield>
    <subfield code="a">SMME</subfield>
    <subfield code="b">SMME</subfield>
    <subfield code="c">EB</subfield>
    <subfield code="d">2024-02-16</subfield>
    <subfield code="l">0</subfield>
    <subfield code="o">610</subfield>
    <subfield code="p">SMME-TH-813</subfield>
    <subfield code="r">2024-02-16</subfield>
    <subfield code="w">2024-02-16</subfield>
    <subfield code="y">THE</subfield>
  </datafield>
</record>
